Hani Hassoun, MD
Myeloma Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Plasma Cell Dyscrasias: Multiple Myeloma
- Amyloidosis
- Light Chain Deposition Disease
Request an Appointment
About Me
- Attending Physician
I am a board-certified hematologist-oncologist with a special interest in plasma cell dyscrasias — a group of disorders that includes multiple myeloma, amyloidosis, light chain deposition disease, POEMS syndrome, and Waldenström’s macroglobulinemia. There have been tremendous advances in this field over the past decade, and several new drugs are available or in development to manage these conditions. With my colleagues at Memorial Sloan Kettering Cancer Center, I have focused on developing and optimizing new approaches to treat these diseases, including both new drugs and new strategies to improve patients’ outcomes.
Read more
In multiple myeloma we currently have several clinical trials that are addressing important questions in patients who are newly diagnosed and have never been treated to better define the role and timing of autologous stem cell transplantation. We are also conducting several clinical trials in patients whose disease has recurred after initial treatment in order to develop new drugs that would be effective against the disease.
Likewise, in the field of amyloidosis and light chain deposition disease, we are currently testing the role of a comprehensive treatment that incorporates autologous stem cell transplantation preceded and followed by more conventional therapies. We are hopeful that this comprehensive treatment will allow optimal control of the disease.
I also have a particular interest in thrombotic complications (blood clotting) that occur in cancer patients and in patients receiving chemotherapy. We are trying to develop prophylactic strategies to decrease the frequency of these common complications in cancer patients using old and newer blood thinners.
A myeloma specialist is a doctor with special training in diagnosing and treating myeloma.
My Specialties
- Plasma Cell Dyscrasias: Multiple Myeloma
- Amyloidosis
- Light Chain Deposition Disease
- Coagulation Disorders in Cancer Patients
Education
- MD, University of Pierre et Marie Curie (Paris, France)
Residencies
- Brigham and Women's Hospital/Harvard Medical School
Awards and Honors
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
Fellowships
- St. Elizabeth's Medical Center/Tufts Medical School
Board Certifications
- Internal Medicine
- Hematology/Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Hassoun sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Hassoun
- A Phase 2 Study of Cyclophosphamide, Bortezomib, Dexamethasone, and Daratumumab in People With Monoclonal Gammopathy of Renal Significance
- Clinical Trials Co-Investigated by Dr. Hassoun
- A Phase 2 Study of Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone in People With Amyloid Light Chain Amyloidosis
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Hassoun’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Hani Hassoun discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].